SCHEMBL4182605

SCHEMBL4182605

COc1cccc(-c2nnc(-c3cccnc3C(N)c3ccncc3)[nH]2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.45
NPY5R Q15761 1/20 0.42
DYRK1A Q13627 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
MAPK14 Q16539 2/20 0.40
MAPK13 O15264 1/20 0.40
RAF1 P04049 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
GCGR P47871 1/20 0.39
NTRK1 P04629 1/20 0.39
CDC7 O00311 1/20 0.39
MGAT2 Q10469 1/20 0.38
KCNA5 P22460 1/20 0.38
GSK3A P49840 3/20 0.37
GSK3B P49841 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172618 0.90 KCNA5 (0.48) AURKANPY5RDYRK1ACLK4PDE4B
SCHEMBL4170892 0.83 TUBB4A (0.42) MAPK1ROCK1KDRKMT2A
SCHEMBL4180853 0.81 KCNA5 (0.40) AURKANPY5RDYRK1ACLK4MGAT2
SCHEMBL6257420 0.78 AURKA (0.47) AURKANPY5RDYRK1ACLK4MAPK14
SCHEMBL4171111 0.76 TEK (0.44) MAPK14MAPK13RAF1MAPK12MAPK11
SCHEMBL4175489 0.76 NPY5R (0.47) NPY5RGSK3AGSK3BCDK1CDK5
SCHEMBL4182606 0.74 CYP1A2 (0.52) AURKADYRK1ACLK4PDE4APDE4B
SCHEMBL4186196 0.74 TUBB4A (0.42) NPY5RDYRK1AKCNA5GSK3BCDK2
SCHEMBL22307327 0.74 AURKA (0.50) AURKANPY5RDYRK1ACLK4GSK3A
SCHEMBL4173391 0.71 AURKA (0.43) AURKANPY5RDYRK1ACLK4GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL AURKA 539/4885NPY5R 4592/4885DYRK1A 4792/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL AURKA 539/4885NPY5R 4592/4885DYRK1A 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.